The 12-Step MedTech Recovery Program: For Founders Who Thought Clearance Was the Hard Part
- May 6
- 4 min read
FDA clearance is not a commercial strategy.
It's permission to start building one.
That distinction matters more than most international MedTech founders realize until they've already arrived in the U.S. market, pitch deck in hand, expecting momentum. What they find instead:
Clinical skepticism
Procurement committees
Reimbursement walls
Hospital IT
And Decision-makers with zero emotional investment in their technology.
Clearance doesn't protect you from any of that.
Over the next 12 weeks, I'm going to break down each of these 12 critical areas every MedTech company needs to address before attempting U.S. market entry. Not theory. Not frameworks that sound good in a boardroom. The actual places where launches stall, pilots die, and cash burns quietly until it's too late.
This post is the overview. The weeks ahead are where it gets useful.
👉 Most founders think they're further along than they are. Take the self-assessment and see where you actually stand.
The 12 Step Recovery Program
Clinical and Research Readiness Clinical data gets physicians on board. But most launches fail not because the data is weak, but because it wasn't designed to speak to everyone in the room. Administration and C-suite don't respond to the same evidence that moves a surgeon. Your research needs to capture clinical outcomes and the operational and economic signals that administration actually buys on. Getting that right starts at the study design level, not after the fact.
Regulatory, Quality, and Risk Architecture Clearance gets you in the door. SOC II, cybersecurity documentation, risk files, and insurance compliance get you through IT and procurement. Hospitals will stall your implementation for six months over gaps you assumed didn't matter. This isn't an area where I'll pretend to be your regulatory counsel, but I maintain a strong referral network of people who are.
Health Economics and Reimbursement Strategy Budget owners, not physicians, control your fate in most institutions. If you can't connect your technology to clinical outcomes, operational efficiency, and financial justification in the same breath, nothing moves. The key word there is "connect" not "imply." Real economics, real impact, no arm-waving. I work on the economics side of this directly and can connect you to the right reimbursement execution partners.
Productization and Technical Readiness FDA clearance means "safe and effective." It does not mean "usable," "integrated," or "commercially deployable." If your product still feels like a research prototype, you're not ready for U.S. hospital procurement. I won't pretend to be your product team, but I know people who can close those gaps, and knowing where to look matters more than most founders expect.
GTM Strategy and Commercial Infrastructure This is where most companies quietly fall apart, and where I spend most of my time. Your go-to-market strategy is not your pitch deck. It's pricing, contracts, segment sequencing, CRM, and the operational processes that hold your launch together. Companies don't fail because the technology is bad. They fail because the commercial foundation was never built.
Commercial and Account Segmentation The U.S. hospital buying process is not uniform. Your ICP, your early-adopter archetype, your system-level decision pathway, each stakeholder's level of influence: these variables determine whether you convert pilots into contracts or stall in perpetual evaluation. Getting this wrong is expensive. Getting it right early is one of the clearest advantages a company can have.
Marketing, Positioning, and Demand Generation Innovation doesn't speak for itself. Physicians, CFOs, IT, procurement, and skeptical department heads all evaluate your technology differently. The goal isn't just consistent messaging; it's putting the right message in front of the right person at the right moment so it actually lands. Peer-to-peer influence will outperform your website every time, and part of building a smart GTM strategy is knowing how to engineer that.
Operational Scalability and Deployment Model If deploying your technology requires heroic effort on your team's part, you're not ready to scale. Hospitals expect clean implementation workflows, training protocols, predictable timelines, and minimal friction. This doesn't have to be complicated. The companies that get deployment right almost always get there by simplifying, not by building more elaborate systems. Keep it simple.
Customer Success and Post-Market Support You're not judged by your pilot. You're judged by whether customers renew. Retention is your revenue engine. Onboarding, support structure, outcome tracking, feedback loops back into product, and a clear plan for account expansion: these are not afterthoughts. They are the difference between a company that grows and one that churns through pilots indefinitely.
Partnership and Ecosystem Strategy Academic partners, channel partners, integration partners, strategic alliances: these are not nice-to-haves. The right relationships materially accelerate trust and adoption in ways that direct sales alone cannot. Building a partnership strategy that actually moves the needle, and identifying the right partners to pursue, is one of the highest-leverage things an early-stage company can do.
Organizational and People Readiness If your internal operations run on adrenaline and informal communication, the U.S. market will expose that quickly. Clear roles, hiring plans, decision rights, and alignment across sales, clinical, and field functions are all commercial infrastructure. Getting the team structure right before the launch pressure hits is a lot easier than fixing it after.
Investor and Board Alignment Clearance creates excitement. Commercialization creates fear. Your board needs to understand required capital, milestone sequencing, U.S. hospital timelines, and the real tradeoffs between growth and burn. Mismatched expectations are a company killer, and they're more common than anyone likes to admit. Getting alignment before you need it is always easier than chasing it during a difficult quarter.
Why This Matters
The U.S. market rewards preparedness, not enthusiasm.
"We'll figure it out as we go" is the fastest path to burned cash, stalled pilots, frustrated investors, and the slow erosion of momentum that's nearly impossible to recover from.
Over the next 12 weeks, I'll go deep on each of these areas: what they actually require, where companies most commonly go wrong, and what good preparation actually looks like.
If you want to know where you stand before we get there, the self-assessment I built will give you an honest read in under 10 minutes.
Your future self will appreciate the reality check.
Comments